

Barbara C Tilley

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4287995/publications.pdf>

Version: 2024-02-01

18
papers

743
citations

687363

13
h-index

839539

18
g-index

18
all docs

18
docs citations

18
times ranked

1113
citing authors

#	ARTICLE	IF	CITATIONS
1	Effect of Creatine Monohydrate on Clinical Progression in Patients With Parkinson Disease. JAMA - Journal of the American Medical Association, 2015, 313, 584.	7.4	192
2	Pragmatic Randomized Optimal Platelet and Plasma Ratios (PROPPR) Trial: Design, rationale and implementation. Injury, 2014, 45, 1287-1295.	1.7	118
3	Making thawed universal donor plasma available rapidly for massively bleeding trauma patients: experience from the Pragmatic, Randomized Optimal Platelets and Plasma Ratios (PROPPR) trial. Transfusion, 2015, 55, 1331-1339.	1.6	73
4	The Next Step Trial: Impact of a Worksite Colorectal Cancer Screening Promotion Program. Preventive Medicine, 1999, 28, 276-283.	3.4	60
5	Official Japanese Version of the International Parkinson and Movement Disorder Society's Unified Parkinson's Disease Rating Scale: Validation Against the Original English Version. Movement Disorders Clinical Practice, 2014, 1, 200-212.	1.5	47
6	Caffeine and Progression of Parkinson Disease. Clinical Neuropharmacology, 2008, 31, 189-196.	0.7	35
7	Handling missing values in the MDS-UPDRS. Movement Disorders, 2015, 30, 1632-1638.	3.9	33
8	<sc>IPMDS</sc>â€Sponsored Scale Translation Program: Process, Format, and Clinimetric Testing Plan for the <sc>MDS</sc>â€<sc>UPDRS</sc> and UDysRS. Movement Disorders Clinical Practice, 2014, 1, 97-101.	1.5	30
9	Crossâ€Cultural Differences of the Nonâ€Motor Symptoms Studied by the Traditional Chinese Version of the International Parkinson and Movement Disorder Society's Unified Parkinson's Disease Rating Scale. Movement Disorders Clinical Practice, 2017, 4, 68-77.	1.5	29
10	A randomized recruitment intervention trial in Parkinsonâ€™s disease to increase participant diversity: early stopping for lack of efficacy. Clinical Trials, 2012, 9, 188-197.	1.6	26
11	Caffeine and Progression of Parkinson Disease. Clinical Neuropharmacology, 2015, 38, 163-169.	0.7	25
12	Caffeine, creatine, GRIN2A and Parkinson's disease progression. Journal of the Neurological Sciences, 2017, 375, 355-359.	0.6	23
13	Design of a cluster-randomized minority recruitment trial: RECRUIT. Clinical Trials, 2017, 14, 286-298.	1.6	23
14	Validation of the Hebrew version of the Movement Disorder Society's Unified Parkinson's Disease Rating Scale. Parkinsonism and Related Disorders, 2017, 45, 7-12.	2.2	9
15	Using increased trust in medical researchers to increase minority recruitment: The RECRUIT cluster randomized clinical trial. Contemporary Clinical Trials, 2021, 109, 106519.	1.8	8
16	Communicating with participants during the conduct of multi-center clinical trials. Clinical Trials, 2016, 13, 592-596.	1.6	7
17	Intent-to-treat analysis of cluster randomized trials when clusters report unidentifiable outcome proportions. Clinical Trials, 2020, 17, 627-636.	1.6	4
18	Costâ€effectiveness evaluation of thePROPPRtrial transfusion protocols. Transfusion, 2020, 60, 922-931.	1.6	1